Osimertinib, sold under the brand name Tagrisso, is a medication used to treat non-small-cell lung carcinomas with specific mutations. It is a third-generation epidermal growth factor receptor tyrosine kinase inhibitor. From Wikipedia
The pharmaceutical giant posts 10% revenue growth, accelerates US manufacturing and R&D plans, and faces legal scrutiny in China over tax and data issues.
